Related news

  1. Oxbryta use and a claim for harm

    FDA grants accelerated approval to Oxbryta

    The FDA approves Oxbryta (voxelotor) under its accelerated-approval pathway for sickle cell patients aged 12 and older, based on the drug’s ability to raise hemoglobin levels — a surrogate endpoint rather than proof of fewer crises or deaths.

    Source: fda.gov

  2. Oxbryta use and a claim for harm

    Pfizer withdraws Oxbryta worldwide

    Pfizer voluntarily withdraws all lots of Oxbryta from markets worldwide and halts its voxelotor trials, citing clinical data showing an imbalance in vaso-occlusive crises and deaths. The FDA tells doctors to stop prescribing it.

    Source: pfizer.com